What top creators are saying about Hims & Hers Health, Inc.(HIMS)

The speaker said he had no opinion on the stock.

A sponsored segment promoted access to weight-loss care, including Wegovy, but provided no financial analysis or investment outlook.

Used only as a comparison for Micron’s low reading on the speaker’s valuation metric; no separate investment thesis is provided.

Shares rose, but the host cited regulatory and legal uncertainty and questioned whether the company has a durable moat beyond marketing.

Discussed as an example of a public company connected to an on-chain meme-token community. The speaker claimed on-chain trading once reached roughly 10% of HIMS stock trading volume, but the proposed marketing and tokenization benefits remain experimental.

The speaker is bullish, citing sales growth, a valuation of about 2x forward revenue, and potential growth from international expansion, branded GLP-1 products, additional services, and an AI-native care experience. Risks include uncertain adoption and approvals, investment needs, and lower EBITDA margins.

The stock has faced broad growth-stock selling and was described as having traded at a low valuation for an extended period; the speaker says to assess its business performance rather than infer fundamentals from price action.

Mentioned as the company referenced by the Boner meme-token theme; no analysis or stock recommendation is provided.

A memecoin was associated with Hims' men’s-health business and a claimed social-media interaction, but no formal company connection or stock recommendation was established.

About 30% of its float was reportedly shorted, which could attract speculative short-squeeze trading, but no squeeze was established as likely. Tokenized stock activity was small relative to the company.

Hims & Hers is referenced as the company behind Bonacoin's theme, with no stock analysis or recommendation.

The speaker described a past short trade that worked well but said he was not currently short and gave no longer-term view.

Presents an attractive entry point driven by strong top-line revenue growth, wearable development, and a distribution partnership role with Novo Nordisk for weight-loss drugs.

Fundamentally undervalued with an attractive Gross Profit over Revenue Growth ratio around 0.1, making it a compelling long-term opportunity despite interest rate-driven drawdowns.

An undervalued growth asset with upcoming catalysts including a full mobile application redesign and international platform integration.

Experiencing strong consumer demand by providing direct access to affordable GLP-1 weight-loss options and bypassing traditional insurance friction via recurring subscriptions.

Despite moving within a 20% volatility band, the valuation is considered way too cheap relative to underlying fundamentals, presenting an attractive entry point for long-term investors.

Highlighted through an on-chain MemeFi tokenized liquidity pair that gained public visibility following engagement from the company's CEO.

Tokenized trading volume remains too negligible relative to its $6.5 billion market cap to influence traditional equity price action or trigger short squeezes.

Tokenized stock traded up to $132 on weekend AMM pools due to severe liquidity imbalances, highlighting counterparty and redemption risks.

Capturing market share in high-demand categories like weight loss and GLP-1 access through end-to-end online visits and direct-to-door delivery.

On-chain paired token demand forces liquidity providers to mint new tokenized shares, translating into real 1:1 backed off-chain share purchases and increased retail search volume.

Recent 18% pullback offers long-term upside driven by an EV/GP/RG ratio of 0.1, a Rule of 40 score of 46, and strong positioning for 2026-2027 peptide distribution approvals.

Highlighted for extreme price dislocations and volatility caused by unbacked on-chain tokenized trading pools outside traditional market hours.

Represents a deep-value opportunity trading at a discounted 0.10 valuation multiple despite resilient underlying fundamentals.

Tokenized pairings with meme coins carry severe volatility and liquidity risks, with retail facing downside risk from inefficient on-chain arbitrage against the underlying equity.

Telehealth stock valued around $6 billion paired with the BONER meme coin in the stock-meme trend.

Referenced as the pairing narrative for the Boner meme token which reached $90M.

Tokenized synthetic weekend trading pairs deviate significantly from real-market closing prices, exposing retail liquidity providers to recurring Monday institutional arbitrage losses.

Noted as having a $6B market capitalization and used as a benchmark valuation comparison

Targeted by speculative MemeFi social trading tokens characterized by insider momentum and rapid liquidity shifts.

Mentioned as a $7 billion market cap stock connected to the BONER token narrative.

Tokenized shares are utilized as real-world asset pairings with meme coins on the Robinhood chain ecosystem.

Purchased as synthetic stock using trading transaction fees generated by satirical meme coin pairs.

Exhibiting strong market presence at a $6 billion market cap, driven by elevated internet search volume for peptides.

Tokenized HIMS stock paired with memecoins on AMMs is driving on-chain premium pricing and liquidity provisioning yields.

Subjected to indiscriminate growth stock selling pressure despite maintaining an organically growing, recession-resistant business detached from interest rate impacts.

Could benefit as companies openly embrace stock-backed meme communities; viewed as a highly convex trade at current prices where investors might regret not holding a small position in the coming weeks.

Subject to artificial equity supply constraints as tokenized shares are locked into on-chain meme coin liquidity pools.

Facilitating friction-free telehealth access to high-demand GLP-1 weight-loss medications, expanding recurring subscription revenue and customer base.

Closed at $28.84 on the NYSE but surged to around $39 (a 37% premium) in onchain tokenized trading due to limited inventory and a float squeeze.

Presents a long-term hyper-growth opportunity in digital health where current valuation does not fully reflect international expansion, GLP-1 distribution, or high-margin product rollouts, though investors should expect continued share price volatility.

Broad-market basket selling has disconnected the stock from its underlying business performance and low-risk balance sheet, creating a buying opportunity in a recession-resistant business.

Viewed as consistently undervalued with strong fundamentals, strong Rule of 40 score, and high-margin upside from GLP-1 drug expansion and future peptide approvals.

The 10% sell-off driven by recycled reports regarding customer returns is a market overreaction with minimal financial impact (~$75,000), offering a value buying opportunity at fundamentally cheap valuation levels.

Placed into Visa's acquirer monitoring program due to elevated subscription chargebacks and cancellations, compounded by high 30%-40% short interest.

Traded up 3.5% as broader healthcare and pharmaceutical names benefited from sector rotation.

Gained 13% as macro liquidity flows lifted high-growth risk-on assets; maintained as a top conviction holding.

Demonstrated significant positive momentum supported by broader inflows into the healthcare sector.

Short-term macro pressure is disconnecting the share price from solid fundamentals, creating a long-term growth opportunity in off-patent GLP-1 and peptide commercialization.